Measurement of Blood Volume Loss During Burn Surgery

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03340116
Collaborator
Daxor Corporation (Industry)
0
1
12
0

Study Details

Study Description

Brief Summary

Burn surgery is associated with significant reductions in hematocrit. However, it is unclear whether these reductions are the result of hemodilution from non-red cell containing intraoperative transfusions or from loss of red blood cells. The investigators will be using the Daxor Blood Volume Analyzer (BVA-100), an FDA approved instrument that can measure total blood volume, plasma volume, and RBC volume using the indicator dilution technique. By comparing pre-operative measurements of blood volume, plasma volume, and RBC volume to that of post-operative measurements after burn surgery, the investigators can determine the primary cause of the reduction in hematocrit associated with burn surgery. The investigators hypothesize that these reductions in hematocrit are primarily the result of hemodilution rather than blood loss and that there will be a statistically significant difference in measured plasma volume from the pre-operative group to the post-operative group.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Burn surgery
  • Diagnostic Test: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Detailed Description

Burn surgery is associated with significant changes (reductions) in hematocrit. However, it is unclear whether these reductions are the result of hemodilution from non-red cell containing intraoperative transfusions or from loss of red blood cells. The investigators will be using the Daxor Blood Volume Analyzer (BVA-100), an FDA approved instrument that can measure total blood volume, plasma volume, and RBC volume using the indicator dilution technique. With this technique, a tracer substance (I-131 albumin) is mixed with an unknown volume. An identical amount of the tracer is mixed into a solution with a known volume. By comparing the concentration of the indicator between the known and unknown volumes, the investigators can determine the volume of the unknown volume (or in this case, the blood volume).

The investigators will be measuring the change in blood volume, plasma volume, and RBC volume from the pre-operative to the post-operative state after completion of burn surgery. We hypothesize that these reductions in hematocrit are primarily the result of hemodilution rather than blood loss and that there will be a statistically significant change in measured plasma volume from the pre-operative to the post-operative measurements.

Average plasma volume for male and female patients is 2950ml SD=590 ml. To detect a 10% increase in plasma volume from hemodilution with a power 0.80 and alpha error 0.05, a one tailed normal distribution t-test determines a sample size fifty. To account for a 10% data loss (technical difficulty, patient withdraw) a sample size of fifty-five would be required.

Fifty-five consecutive adult patients (18 years or older) having burn surgery will be enrolled. Patients with recognized coagulopathy will be excluded. The outcome variables included blood volume (BV, ml), plasma volume (PV, ml) and red blood cell volume (RBCV, ml). All three outcome variables will be measured at two time points; pre-surgery and post-surgery. The pre-surgery measurement will be collected precisely after induction of general anesthesia but prior to surgery start. The post-surgery measurement will be taken immediately after the operation and after all intraoperative red blood cell transfusions are complete. For those patients receiving blood transfusions in the operating room prior to all data collection points, the transfused RBC volume will be recorded and subtracted from the RBCV measured after the transfusion. Transfused RBCV will take into account Hct of 60% for pRBCs. Additional baseline information, including age (year), sex (male, female), weight (kg), and surgery type, will be collected. For the tracer dilution method, the following blood samples will be collected: a baseline (no radiation sample), a first sample 12 minutes after injection (after complete mixing in the blood volume) and additional samples every 6 minutes for at least three successive timed sample points. These multiple timed sample points produce a logarithmic curve of radiation over time, as only a small fraction of albumin leaves the blood volume into the interstitial space. The investigators will compare the pre-operative and post-operative blood volume, RBC volume, and plasma volume measurements to determine if the decrease in hematocrit associated with burn surgery is truly due to hemodilution or loss of RBC volume.

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Measurement of Plasma Volume, RBC Volume, and Total Blood Volume Using Daxor Blood Volume Analyzer (BVA-100) in Burn Surgery Patients Pre-operatively and Post-operatively to Determine if Blood Loss During Burn Surgery is Primarily Due to Either Loss of RBC Volume or Hemodilution
Anticipated Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Jan 1, 2021
Anticipated Study Completion Date :
Jan 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Pre-operative cohort

This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention

Diagnostic Test: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Post-operative cohort

This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.

Procedure: Burn surgery
Burn surgery including wound debridement, skin grafting

Diagnostic Test: Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100

Outcome Measures

Primary Outcome Measures

  1. Change in measured plasma volume [Pre-operative period after intubation, but before surgery start and post-operative period after surgery stop and after all intraoperative blood transfusions are complete]

    Measured plasma volume using Daxor BVA-100

  2. Change in measured RBC volume [Pre-operative period after intubation, but before surgery start and post-operative period after surgery stop and after all intraoperative blood transfusions are complete]

    Measured RBC volume using Daxor BVA-100

  3. Change in measured total blood volume [Pre-operative period after intubation, but before surgery start and post-operative period after surgery stop and after all intraoperative blood transfusions are complete]

    Measured total blood volume using Daxor BVA-100

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Sustained thermal burn of a depth that is deep partial thickness to full thickness and requires operative management

  • Burn excision must occur within one week of thermal injury

  • Burn size between 10-50% of total body surface area

  • Must survive initial resuscitation

  • Must consent for blood product transfusion

  • Male or non-pregnant female

Exclusion Criteria:
  • Cause of burn other than thermal injury (ie electrical or chemical injury)

  • Women who are nursing, pregnant, or think they may be pregnant

  • Patients with recognized coagulopathy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virginia Commonwealth University Medical Center Richmond Virginia United States 23223

Sponsors and Collaborators

  • Virginia Commonwealth University
  • Daxor Corporation

Investigators

  • Principal Investigator: Mark Nelson, MD, VCU Medical Center
  • Principal Investigator: Michael Feldman, MD, VCU Medical Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT03340116
Other Study ID Numbers:
  • HM20015231
  • HM20011159
First Posted:
Nov 13, 2017
Last Update Posted:
Jan 13, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2020